ArticleChemical communications (Cambridge, England)2014
A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease.
Article in Chemical communications (Cambridge, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 101 citations in OpenAlex.
- Recent Advances in Organofluoroprobes for Brain Imaging: Progress, Challenges, and Future Directions.ACS pharmacology & translational science · 2026Review
- 1,3,2-Dioxaborine-based mero-polyanionic dyes: high-extinction NIR-absorbing polymethines.RSC advances · 2026Article
- SARS-CoV-2 induces Alzheimer's disease-related amyloid-β pathology in ex vivo human retinal explants and retinal organoids.Science advances · 2025Article
- Half-Curcumin-Based Chemiluminescence Probes and Their Applications in Detecting Quasi-Stable Oxidized Proteins.Angewandte Chemie (International ed. in English) · 2024Article
- A novel BODIPY-based theranostic agent forRSC medicinal chemistry · 2024Article
- Recent progress of small-molecule-based theranostic agents in Alzheimer's disease.RSC medicinal chemistry · 2023Review
- A Photolabile Curcumin-Diazirine Analogue Enables Phototherapy with Physically and Molecularly Produced Light for Alzheimer's Disease Treatment.Angewandte Chemie (International ed. in English) · 2023Article
- Two-Photon Fluorescent Probes for Amyloid-β Plaques Imaging In Vivo.Molecules (Basel, Switzerland) · 2023Review
- Diverse and Composite Roles of miRNA in Non-Neuronal Cells and Neuronal Synapses in Alzheimer's Disease.Biomolecules · 2022Review
- Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research.Molecules (Basel, Switzerland) · 2022Review
- Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes forTheranostics · 2022Article
- Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.Bioorganic chemistry · 2021Review
- Curcumin Conjugates of Non-steroidal Anti-Inflammatory Drugs: Synthesis, Structures, Anti-proliferative Assays, Computational Docking, and Inflammatory Response.ChemistryOpen · 2020Article
- Curcumin in Health and Diseases: Alzheimer's Disease and Curcumin Analogues, Derivatives, and Hybrids.International journal of molecular sciences · 2020Review
- CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques.Molecules (Basel, Switzerland) · 2020Article
- Frontiers in Probing Alzheimer's Disease Biomarkers with Fluorescent Small Molecules.ACS central science · 2019Review
- Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics.Acta neuropathologica communications · 2018Article
- Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases.International journal of molecular sciences · 2018Review
- Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease.Neural regeneration research · 2018Review
- Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging.Biological psychiatry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
In this report, we designed a highly bright bifunctional curcumin analogue CRANAD-28. In vivo two-photon imaging suggested that CRANAD-28 could penetrate the blood brain barrier (BBB) and label plaques and cerebral amyloid angiopathies (CAAs). We also demonstrated that this imaging probe could inhibit the crosslinking of amyloid beta induced either by copper or by natural conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.